Davis Polk advised J.P. Morgan Securities LLC and Goldman, Sachs & Co. as representatives of the several underwriters in connection with an offering of 5,750,000 shares of common stock of ChemoCentryx, Inc., including 750,000 shares from the exercise of the underwriters’ over-allotment option. The gross proceeds from the offering were $69 million.
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer by targeting the chemokine system. ChemoCentryx is headquartered in Mountain View, California.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Meng Lai and Paul Weitzel. Associates Bruce Rose-Innes and David R. Bauer provided intellectual property advice. Partner Rachel D. Kleinberg provided tax advice. Members of the Davis Polk team are based in the Menlo Park and New York offices.
